| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Top1
(±)-Evodiamine targets multiple cellular pathways. It inhibits topoisomerase I (Top1), an enzyme essential for DNA replication and transcription. The compound also inhibits NF-κB activation, suppressing invasion and promoting apoptosis. It downregulates IGF-1/HIF-1α and IL-6/STAT pathways, contributing to its anti-obesity and anti-diabetic effects. |
|---|---|
| ln Vitro |
(±)-Evodiamine demonstrates potent in vitro antitumor activity against a wide variety of tumor cell lines by inducing apoptosis. It exhibits anti-inflammatory and anti-obesity effects. The compound's activity is assessed in cell viability assays, apoptosis assays, and NF-κB activation assays using cancer cell lines and immune cells.
|
| ln Vivo |
In vivo activity of (±)-evodiamine has been suggested by its anti-inflammatory, anti-obesity, and antitumor effects. The compound has potential for in vivo efficacy in models of cancer, inflammation, and metabolic disorders. Further in vivo studies are needed to evaluate its pharmacokinetic properties, efficacy, and safety profile.
|
| Enzyme Assay |
In vitro enzyme assays for (±)-evodiamine involve measuring its inhibition of topoisomerase I activity. The assay typically uses purified Top1 enzyme and measures the relaxation of supercoiled DNA in the presence of the compound. NF-κB activation can be assessed using reporter gene assays or by measuring NF-κB target gene expression.
|
| Cell Assay |
In vitro cellular assays for (±)-evodiamine involve treating cancer cell lines with varying concentrations of the compound and measuring cell viability using MTT or other assays. Apoptosis is evaluated by Annexin V staining, caspase activity assays, or DNA fragmentation analysis. Anti-inflammatory activity is assessed by measuring cytokine production in activated immune cells.
|
| Animal Protocol |
In vivo animal experiments for (±)-evodiamine would typically involve administering the compound to animal models of cancer, inflammation, or obesity. Efficacy is evaluated by measuring tumor growth inhibition, inflammatory markers, or body weight changes. The compound's anti-obesity effects can be assessed by measuring IGF-1/HIF-1α and IL-6/STAT pathway modulation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for (±)-evodiamine are limited. The compound has a molecular weight of 303.36 and a molecular formula of C19H17N3O. It should be stored under recommended conditions as specified in the Certificate of Analysis. Its absorption, distribution, metabolism, and excretion properties have not been fully characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for (±)-evodiamine are limited. As a natural product-derived compound, it is generally considered to have moderate toxicity, but comprehensive toxicological studies have not been reported. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
LSM-6483 belongs to the β-carboline class of compounds.
(±)-Evodiamine (CAS#: 518-18-3) has the molecular formula C19H17N3O and a molecular weight of 303.36. It is a quinazolinocarboline alkaloid from Evodiae fructus that inhibits topoisomerase I and NF-κB activation. The compound exhibits anti-inflammatory, anti-obesity, and antitumor effects by inducing apoptosis. It is for research use only. |
| Molecular Formula |
C19H17N3O
|
|---|---|
| Molecular Weight |
303.36
|
| Exact Mass |
303.137
|
| CAS # |
518-18-3
|
| Related CAS # |
Evodiamine;518-17-2
|
| PubChem CID |
151289
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
575.1±50.0 °C at 760 mmHg
|
| Melting Point |
272 °C
|
| Flash Point |
301.6±30.1 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.764
|
| LogP |
1.64
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
23
|
| Complexity |
495
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1C2C3=C(CCN2C(=O)C4=CC=CC=C41)C5=CC=CC=C5N3
|
| InChi Key |
TXDUTHBFYKGSAH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H17N3O/c1-21-16-9-5-3-7-14(16)19(23)22-11-10-13-12-6-2-4-8-15(12)20-17(13)18(21)22/h2-9,18,20H,10-11H2,1H3
|
| Chemical Name |
21-methyl-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,15,17,19-heptaen-14-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 10 mg/mL (32.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (3.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2964 mL | 16.4821 mL | 32.9641 mL | |
| 5 mM | 0.6593 mL | 3.2964 mL | 6.5928 mL | |
| 10 mM | 0.3296 mL | 1.6482 mL | 3.2964 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
